Estimating in vivo airway surface liquid concentration in trials of inhaled antibiotics

Journal of Aerosol Medicine: Deposition, Clearance, and Effects in the Lung

Volumn 20, Issue 3, 2007, Pages 282-293

  Hasan, M A ^a   Lange, C F ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Aerosol; Airway surface liquid modeling; Inhaled antibiotics; Lung simulation

Indexed keywords

ANTIBIOTIC AGENT; TAUROLIDINE; TOBRAMYCIN;

AEROSOL; AIRWAY; ARTICLE; BODY FLUID; BURKHOLDERIA CEPACIA; CONCENTRATION (PARAMETERS); CYSTIC FIBROSIS; DRUG EFFICACY; HUMAN; IN VIVO STUDY; INHALATION; LIQUID; LUNG; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; MEASUREMENT; MINIMUM INHIBITORY CONCENTRATION; NEBULIZER; PSEUDOMONAS AERUGINOSA; SIMULATION; TRACHEOBRONCHIAL TREE;

ADMINISTRATION, INHALATION; AEROSOLS; ANTI-BACTERIAL AGENTS; BURKHOLDERIA CEPACIA; BURKHOLDERIA INFECTIONS; COMPUTER SIMULATION; CYSTIC FIBROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESEARCH DESIGN; RESPIRATORY MECHANICS; RESPIRATORY SYSTEM; SPUTUM; TAURINE; THIADIAZINES; TOBRAMYCIN;

EID: 34748875208     PISSN: 08942684     EISSN: None     Source Type: Journal    
DOI: 10.1089/jam.2007.0603     Document Type: Article

References (54)

1. Torres-Viera, C., C. Thauvin-Eliopoulos, M. Souli, P. DeGirolami, M.G. Farris, C.B. Wennersten, R.D. Sofia, and G.M. Eliopoulos. 2000. Activities of taurolidine in vitro and in experimental enterococcal endocarditis. Antimicrob. Agents Chemother. 44:1720-1724.
2. McCourt, M., J.H. Wang, S. Sookhai, and H.P. Redmond. 2000. Taurolidine inhibits tumor cell growth in vitro and in vivo. Ann. Surg. Oncol. 7:685-691.
3. Shrayer, D.P., H. Lukoff, T. King, and P. Calabresi. 2003. The effect of taurolidine on adherent and floating subpopulations of melanoma cells. Anticancer Drugs 14:295-303.
4. Bedrosian, I., R.D. Sofia, S.M. Wolff, and C.A. Dinarello. 1991. Taurolidine, and analogue of the amino acid taurine, supresses interleukin 1 and tumor necrosis factor synthesis in human peripheral blood mononuclear cells. Cytokine 3:568-575.
5. Polaschegg, H.D. 2000. Taurolidine, a new antimicrobial catheter lock solution. Dial. Times 7:1-8.
6. Baker, D.M., J.A. Jones, J.S. Nguyen-Van-Tam, J.H. Lloyd, D.L. Morris, J.B. Bourke, R.J. Steele, and J.D. Hardcastle. 1994. Taurolidine peritoneal lavage as prophylaxis against infection after elective colorectal surgery. Br. J. Surg. 8:1054-1056.
7. Willatts, S.M., S. Radford, and M. Leitermann. 1995. Effect of the antiendotoxic agent, taurolidine, in the treatment of sepsis syndrome: a placebo-combined, double-blind trial. Crit. Care Med. 23:1033-1039.
8. Blenkharn, J.I. 1986. Prevention of septic complications associated with TPN. J. Parenter. Enter. Nutr. 10:436-437.
9. Betjes, M.G.H., and M.V. Agteren. 2004. Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution. Nephrol. Dial. Transplant. 19:1546-1551.
10. Ledson, M.J., M.J. Gallagher, M. Robinson, C. Cowperthwaite, T. Williets, C.A. Hart, and M.J. Walshaw. 2002. A randomized double-blinded placebo-controlled crossover trial of nebulized taurolidine in adult cystic fibrosis patients infected with burkholderia cepacia. J. Aerosol Med. 15:51-57.
11. Anderson, S.D., J.P. Seale, P. Rozea, L. Bandler, G. Theobald, and D.A. Lindsay. 1976. Inhaled and oral salbutamol in exercise-induced asthma. Am. Rev. Respir Dis. 114:493-500.
12. Neville, A., J.B.D. Palmer, J. Gaddie, C.S. May, K.N.V. Palmer, and L.E. Murchison. 1977. Metabolic effects of salbutamol: comparison of aerosol and intravenous administration. Br. Med. J. 1:413-414.
13. Gonda, I. 2004. Targeting by deposition. In A.J. Hickey, ed. Pharmaceutical Inhalation Aerosol Technology. Marcel Dekker Inc., New York, 65-88.
14. Taulbee, D.B., and C.P. Yu. 1975. A theory of Aerosol deposition in the human respiratory tract. J. Appl. Physiol. 38:77-85.
15. Scott, W.R., and D.B. Taulbee. 1985. Aerosol deposition along the vertical axis of the lung. J. Aerosol Sci. 16:323-333.
16. Ferron, G.A., W.G. Kreyling, and B. Haider. 1988. Measurement of total and regional deposition of inhaled particles in the human respiratory tract. J. Aerosol Sci. 19:611-631.
17. Rudolf, G., J. Gebhart, J. Heyder, Ch.F. Schiller, and W. Stahlhofen. 1986. An empirical formula describing aerosol deposition in man for any particle size. J. Aerosol Sci. 17:350-355.
18. Finlay, W.H., and K.W. Stapleton. 1995. The effect on regional lung deposition of coupled heat and mass transfer between hygroscopic droplets and their surrounding phase. J. Aerosol Sci. 26:655-670.
19. Finlay, W.H. 2001. The Mechanics of Inhaled Pharmaceutical Aerosols: An Introduction. Academic Press. London, 8-9.
20. Finlay, W.H., C.F. Lange, M. King, and D.P. Speert. 2000. Lung delivery of aerosolized dextran. Am. J. Respir. Crit. Care Med. 161:91-97.
21. Lange, C.F., E.W. Robert, R.E. Hancock, J. Samuel, and W.H. Finlay. 2001. In vitro aerosol delivery and regional airway surface liquid concentration of a liposomal cationic peptide. J. Pharm. Sci. 90:1647-1657'.
22. Sweeney, L.G., L.Z. Wang, R. Loebenberg, J.P. Wong, C.F. Lange, and W.H. Finlay. 2005. Spray-Freeze dried liposomal ciprofloxacin powder for inhaled aerosol drug delivery. Int. J. Pharm. 305:180-185.
23. Wang, Z., H.T. Chen, W. Roa, and W.H. Finlay. 2003. Farnesol for aerosol inhalation: nebulization and activity against human lung cancer cells. J. Pharm. Sci. 6:95-100.
24. Desai, T.R., G.J. Tyrrell, T. Ng, and W.H. Finlay. 2003. In vitro evaluation of nebulization properties, antimicrobial activity and regional airway surface liquid concentration of liposomal polymyxin B sulfate. Pharm. Res. 20:442-447.
25. Finlay, W.H., M. Hoskinson, and K.W. Stapleton. 1998. Can models be trusted to subdivide lung deposition into alveolar and tracheobronchial fractions? In Respiratory Drug Delivery VI. Interpharm Press, Buffalo Grove, IL. 235-242.
26. Finlay, W.H., K.W. Stapleton, H.K. Chan, P. Zuberbuhler, and I. Gonda. 1996. Regional deposition of inhaled hygroscopic aerosols: in vivo SPECT compared with mathematical deposition modelling. J. Appl. Physiol. 81:374-383.
27. Finlay, W.H., K.W. Stapleton, and P. ZuberBuhler. 1998. Variations in predicted regional lung deposition of salbutamol sulphate between 19 nebulizer types. J. Aerosol Med. 11:65-80.
28. Phillips, C.G., S.R. Kaye, and R.C. Schroter. 1994. A diameter-based reconstruction of the branching pattern of the human bronchial tree. Part I. Description and application. Respir. Physiol. 98:193-217.
29. Haefeli-Bleuer, B., and E.R. Weibel. 1988. Morphometry of the human pulmonary acinus. Anatom. Rec. 220:401-414.
30. Chan, T.L., and M. Lippmann. 1980. Experimental measurements and empirical modelling of the regional deposition of inhaled particles in humans. Am. Ind. Hyg. Assoc. J. 41:399-409.
31. Pich, J. 1972. Theory of gravitational deposition of particles from laminar flows in channels. J. Aerosol Sci. 3:351-361.
32. Heyder, J., and J. Gebhart. 1977. Gravitational deposition of particles from laminar aerosol flow through inclined circular tubes. J. Aerosol Sci. 6:311-328.
33. Gormley, P.G., and K. Kennedy. 1949. Diffusion from a stream flowing through a cylindrical tube. Proc. R. Irish. Soc. 52A:163.
34. Rudolf, G., R. Köbrich, and W. Stahlhofen. 1990. Modelling and algebraic formulation of regional deposition in man. J. Aerosol Sci. 21:S403-S406.
35. Finlay, W.H. 1998. Estimating the type of hygroscopic behaviour exhibited by aqueous droplets. J. Aerosol Med. 11:221-229.
36. Widdicombe, J.G. 1997. Airway surface liquid: concepts and measurements. In D.F. Rogers and M.I. Lethem, eds. Airway Mucus: Basic Mechanisms and Clinical Perspectives. Birkhäuser, Basel, 1-17.
37. Serafini, S.M., and E.D. Michaelson. 1977. Length and distribution of cilia in human and canine airways. Bull. Eur. Physiopathol. Respir. 13:551-559.
38. Davis, C.W. 1997. Goblet cells: physiology and pharmacology. In D.F. Rogers and M.I. Lethem, eds. Airway Mucus: Basic Mechanisms and Clinical Perspectives. Birkhäuser, Basel, 149-177.
39. Plopper, C.G., J.G. Heidsiek, A.J. Weir, J.A.St. George, and D.M. Hyde. 1989. Tracheobronchial epithelium in the adult rhesus monkey: a quantitative histochemical and ultrastructural study. Am. J. Anat. 184:31-40.
40. Stahlhofen, W., J. Gebhart, and J. Heyder. 1980. Experimental determination of the regional deposition of aerosol particles in the human respiratory tract. Am. Ind. Hyg. Assoc. J. 41:385-398.
41. Wanner, A., M. Salathe, and T.G. O'Riorda. 1996. Mucociliary clearance in the airways. Am. J. Resp. Crit. Care Med. 154:1868-1902.
42. Sinicropi, D.V., M. Williams, W.S. Prince, J.A. Lofaren, M. Lucus, A. Devault, S. Baughman, M. Nash, H. Fuchs, A. Shak, and the DNase Clinical Investigators. 1994. Sputum pharmacodynamics and pharmacokinetics of recombinant human DNase I in cystic fibrosis. Am. J. Respir. Crit. Care Med. 149:A671.
43. Ramsey, B.W., M.S. Pepe, J.M. Quan, K.L. Otto, A.B. Montgomery, J.W. Warren, M. Vasilijev-K, D. Borowitz, C.M. Bowman, B.C. Marshall, S. Marshall, and A.L. Smith. 1999. Intermittent administration of inhaled tobramycin in patients with Cystic Fibrosis. N. Engl. J. Med. 340:23-30.
44. Vinita B.P., and C.N. Milap. 2001. Efficacy and safety of aerosolized tobramycin in cystic fibrosis. Pediatr. Pulmonol. 32:314-327.
45. Ledson, M.J., R.P. Convery, M.J. Gallagher, and M.J. Walshaw. 1997. Taurolidine in adult cystic fibrosis patients colonised with epidemic Burkholderia Cepacia, Thorax 52:S16.
46. Ledson, M.J., C. Cowperthwaite, M.J. Walshaw, M.J. Gallagher, T. Williets, and C.A. Hart. 2000. Nebulized taurolidine and B cepacia bronchiectasis. Thorax 55:91-93.
47. Keller, M., A. Bucholski, G. Lang, and H. Meyer. 2005. In-vitro equivalence and shorter nebulization time using a novel Tobramycin (100 mg/ml) solution and eflow® compared to TOBI® (300 mg/5 ml) nebulized by the PARI LC PLUS®. In International Conference of the American Thoracic Society (ATS), May 20-25, 2005, San Diego, CA (poster # 2287).
48. Task Group on Lung Dynamics. 1966. Deposition and retention models for internal dosimetry of the human respiratory tract. Health Phys. 12:173-207.
49. Speirs, R.J., B.A. Schaeffler, and P.B. Challoner. 2005. Method and unit dose formulations for the inhalation administration of tobramycin. United States Patent, US 6,890,907 B2.
50. Levy, J., A.L. Smith, M.A. Kenny, B. Ramsey, and F.D. Schoenknecht. 1983. Bioactivity of gentamicin in purulent sputum from patients with cystic fibrosis or bronchiectasis: comparison with activity in serum. J. Infect. Dis. 148:1069-1076.
51. Mendelman, P.M., A.L. Smith, J. Levy, A. Weber, B. Ramsey, and R.L. Davis. 1985. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am. Rev. Respir. Dis. 132:761-765.
52. Govan, J.R., and V. Deretic. 1996. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol. Rev. 60:539-574.
53. Sajjan, U.S., and J.F. Forstner. 1992. Identification of the mucin-binding adhesion of Pseudomonas cepacia isolated from patients with cystic fibrosis. Infect. Immun. 60:1434-1440.
54. Dietrich, H. 2004. Peritoneal dialysis solution with taurolidine. United States Patent 6803363.